Epitherapeutics is currently building a strong IPR platform based on proprietary knowledge within histone demethylases and methyltransferases and via in-house drug discovery efforts to identify small molecule inhibitors of key enzymes within the family targeting unmet medical needs.
EpiTherapeutics is constantly seeking collaborations with new investors and pharma companies in order to leverage biological/oncological insight in the field of epigenetics.
